An Open-label, Phase 2a Study to Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients With Neovascular Age-related Macular Degeneration
Latest Information Update: 22 Jun 2023
At a glance
- Drugs Pazopanib (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors GSK
Most Recent Events
- 30 Sep 2014 New trial record